Citigroup’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Citigroup’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-206,400	Closed	-$1.3M	–	6032
2022 Q4	$1.3M	Hold	206,400	–	–	﹤0.01%	2380
2022 Q3	$1.06M	Buy	206,400 +128,400	+165%	+$806K	﹤0.01%	2673
2022 Q2	$488K	Buy	+78,000	New	+$263K	﹤0.01%	3252
2019 Q4	–	Sell	-391	Closed	-$5K	–	7863
2019 Q3	$5K	Sell	391 -1,093	-74%	-$18K	﹤0.01%	7363
2019 Q2	$22K	Buy	1,484 +544	+58%	+$14.6K	﹤0.01%	7046
2019 Q1	$40K	Sell	940 -46	-5%	-$1.94K	﹤0.01%	6526
2018 Q4	$41K	Buy	986 +20	+2%	+$899	﹤0.01%	6409
2018 Q3	$46K	Buy	966 +658	+214%	+$33K	﹤0.01%	6595
2018 Q2	$15K	Buy	+308	New	+$17.1K	﹤0.01%	7059

Citigroup's FSTX Position: Q1 2023 in Review

Citigroup sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 206,400 shares — an estimated $1.3M sold.

Citigroup first reported a position in FSTX in Q2 2018 and held it in 9 quarters. The position peaked at $1.3M in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Citigroup reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citigroup sold 206,400 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.3M.
Citigroup first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2018 and held it in 9 quarters.
Citigroup's F-star Therapeutics, Inc. Common Stock position peaked at $1.3M in Q4 2022.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.